237 related articles for article (PubMed ID: 27659512)
1. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions.
Rangel EB
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1585-605. PubMed ID: 25255841
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
4. A drug safety evaluation of everolimus in kidney transplantation.
Holdaas H; Midtvedt K; Åsberg A
Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
[TBL] [Abstract][Full Text] [Related]
5. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.
Rangel EB
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1531-48. PubMed ID: 22978385
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.
Vidigal AC; de Lucena DD; Beyerstedt S; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2023; 19(7):405-427. PubMed ID: 37542452
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus and everolimus in kidney transplantation.
Moes DJ; Guchelaar HJ; de Fijter JW
Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
10. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
11. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
13. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
14. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
[TBL] [Abstract][Full Text] [Related]
15. Minimization protocols in pancreas transplantation.
Cantarovich D; Vistoli F
Transpl Int; 2009 Jan; 22(1):61-8. PubMed ID: 18713147
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation.
de Paula MI; Medina Pestana JO; Nicolau Ferreira A; Pontello Cristelli M; Fabiano Franco M; Aguiar WF; Tedesco-Silva H; Rosso Felipe C
Ther Drug Monit; 2016 Feb; 38(1):22-31. PubMed ID: 26121616
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of mTORi based immunosuppression for renal transplantation in India.
Chacko B
Clin Transplant; 2012; 26(1):1-15. PubMed ID: 21906172
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
20. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T
Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
